January 11, 2010 – A hypertension drug using a combination of telmisartan/amlodipine, which requires less-frequent dosing than Novartis's Diovan/Tareg (valsartan), may earn 30 percent patient share according to surveyed U.S. cardiologists. Similarly, in Europe, the agent would earn comparable patient share of 25 percent according to surveyed European cardiologists.

January 8, 2010 – Transradial angiography leads to reduced patient complications, faster recovery time and decreased hospital costs, according to cardiologists at the University of Illinois at Chicago (UIC) and Jesse Brown VA medical centers. They are among the first in the Chicago area to offer the new approach to heart angiograms and clearing blocked arteries.

January 7, 2010 – Doctors with Virginia Interventional and Vascular Associates (VIVA) report success in treating acute deep vein thrombosis (DVT) with a procedure called isolated pharmacomechanical thrombolysis (IPMT). The treatment has been used for the past two years to destroy clots much faster than traditional therapies.

January 6, 2010 - The image quality of multidetector computed tomography (MDCT) scans used for the noninvasive detection of coronary artery disease can be significantly affected by patient characteristics, such as ethnicity, body mass index (BMI), and heart rate.

January 6, 2010 – Two validation studies for a wireless, hand-held, patient-activated device that records and transmits reconstructed 12-lead ECGs confirmed the product's ability to accurately provide remote patient monitoring.

January 5, 2010 – In vivo and in vitro data released yesterday shows a new bioresorbable stent platform allows for complete endothelialization with little inflammation after one month.

January 4, 2010 – The first patient was enrolled the TAXUS Liberte arm of the Dual Anti-Platelet Therapy (DAPT) Study, evaluating the TAXUS Liberté stent in combination with a dual anti-platelet therapy drug that includes aspirin and Effient.

January 4, 2010 – The FDA's permission is sought to allow a safety and feasibility trial for the PHOENIX System, which allows tissue stimulation and injections of biologic or pharmacologic agents to the myocardium. The system is designed to treat patients with refractory angina.